Codiak BioSciences (NASDAQ:CDAK) Rating Lowered to Hold at Zacks Investment Research

Codiak BioSciences (NASDAQ:CDAKGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Codiak BioSciences Inc. is a clinical-stage biopharmaceutical company. It is focused on development of exosome-based therapeutics for spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. Codiak BioSciences Inc. is based in CAMBRIDGE, Mass. “

CDAK has been the topic of a number of other research reports. Wedbush lowered their price objective on Codiak BioSciences from $34.00 to $24.00 and set an “outperform” rating on the stock in a report on Tuesday, February 22nd. The Goldman Sachs Group initiated coverage on Codiak BioSciences in a report on Friday, February 11th. They issued a “buy” rating and a $19.00 price objective on the stock.

Shares of NASDAQ CDAK traded down $0.40 during midday trading on Tuesday, reaching $3.31. 100,190 shares of the company were exchanged, compared to its average volume of 173,432. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. Codiak BioSciences has a 1 year low of $3.27 and a 1 year high of $27.09. The stock has a fifty day simple moving average of $5.10 and a 200 day simple moving average of $9.18. The stock has a market cap of $74.46 million, a P/E ratio of -1.91 and a beta of 4.73.

Codiak BioSciences (NASDAQ:CDAKGet Rating) last released its quarterly earnings results on Thursday, March 10th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.03) by $0.28. Codiak BioSciences had a negative return on equity of 135.41% and a negative net margin of 162.01%. The firm had revenue of $7.70 million for the quarter, compared to analyst estimates of $4.54 million. As a group, analysts forecast that Codiak BioSciences will post -2.63 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its position in shares of Codiak BioSciences by 11.3% during the 3rd quarter. Geode Capital Management LLC now owns 229,941 shares of the company’s stock valued at $3,754,000 after acquiring an additional 23,364 shares during the period. Metropolitan Life Insurance Co NY acquired a new stake in shares of Codiak BioSciences during the 3rd quarter valued at approximately $84,000. Citigroup Inc. lifted its position in shares of Codiak BioSciences by 143.0% during the 3rd quarter. Citigroup Inc. now owns 1,815 shares of the company’s stock valued at $30,000 after acquiring an additional 1,068 shares during the period. BlackRock Inc. lifted its position in shares of Codiak BioSciences by 4.8% during the 3rd quarter. BlackRock Inc. now owns 926,179 shares of the company’s stock valued at $15,125,000 after acquiring an additional 42,013 shares during the period. Finally, Oracle Investment Management Inc. lifted its position in shares of Codiak BioSciences by 3.1% during the 3rd quarter. Oracle Investment Management Inc. now owns 700,000 shares of the company’s stock valued at $11,431,000 after acquiring an additional 21,300 shares during the period. Institutional investors own 61.27% of the company’s stock.

Codiak BioSciences Company Profile (Get Rating)

Codiak BioSciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors.

See Also

Get a free copy of the Zacks research report on Codiak BioSciences (CDAK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Codiak BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codiak BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.